Tavistock Life Sciences
VC Fund
Windermere, United States
Tavistock Life Sciences is a venture capital investment firm specialized in earl-stage investments.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Tavistock Life Sciences invests in
BiotechnologyHealth CareMedicalBiopharmaTherapeutics
Stages Tavistock Life Sciences invests in
Series BSeries CPost-IPO EquityPre-SeedSeries A
Countries Tavistock Life Sciences invests in
United StatesCanadaAustraliaUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Biotechnology 11 (55%)
- Health Care 9 (45%)
- Medical 5 (25%)
- Biopharma 4 (20%)
- Therapeutics 3 (15%)
Stage
- Series B 4 (20%)
- Series C 4 (20%)
- Post-IPO Equity 4 (20%)
- Pre-Seed 2 (10%)
- Series A 1 (5%)
Country
- United States 10 (50%)
- Canada 2 (10%)
- Australia 1 (5%)
- United Kingdom 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Joe Lewis
Founder & Chairman
|
Founder & Chairman | Total investments: 0 | Find email | |
|
Christopher Fuglesang
Team Member
|
Team Member | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kinotek
|
Kinotek is a digital health platform revolutionizing musculoskeletal treatment and care. Using groundbreaking motion capture technology combined with a proprietary neural network algorithm, our platform digitizes whole-body movements and produces compelling dashboards and visualizations for clinicians. No other company has combined the set ofmetrics, features and ease-of-use to support physical therapists, chiropractors, sports coaches, and other clinicians focused on movement health. | $600K / Pre-Seed / Feb 17, 2021 | |
Nuvation Bio
|
Nuvation Bio, is a privately-held biopharmaceutical company currently operating in stealth mode that is focused on the development of next generation therapies that will target the foremost unmet needs in oncology. Nuvation Bio's proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drugdevelopment candidates. Nuvation Bio was founded in 2018 by industry veteran David Hung, M.D., who previously founded and served as President and Chief Executive Officer of Medivation. Nuvation Bio has offices in New York and San Francisco. | $502M / Post-IPO Equity / Feb 11, 2021 | |
AgeRate
|
AgeRate is a developer of a biotechnology platform that helps track aging in real time. This platform utilizes predictive algorithms with multi-omic datasets to derive meaningful insights into health and longevity. The company's first product allows consumers to track their age rate and discover how they can alter their lifestyle habits toslow or reverse aging. | $250K / Pre-Seed / Sep 01, 2020 | |
Mereo Biopharma
|
Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&Lconstraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation.Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON.Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications. | $70M / Post-IPO Equity / Jun 04, 2020 | |
Avidity Biosciences
|
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $16M / Series B / Oct 17, 2018 | |
Inseego
|
Inseego is a global provider of software-as-a-service and solutions for the Internet of Things. It sells its telematics solutions under the Ctrack brand, including its fleet management, asset tracking, and monitoring, stolen vehicle recovery, and usage-based insurance platforms. Inseego also sells business connectivity solutions and devicemanagement services through Novatel Wireless, Inc. and Feeney Wireless ("FW"). The company was founded in 1996 and is headquartered in San Diego, California. | $19.7M / Post-IPO Equity / Aug 07, 2018 | |
G1 Therapeutics
|
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $47M / Series C / May 11, 2016 | |
Kura Oncology
|
At Kura Oncology, They are committed to realizing the promise of precision medicines for cancer.The genomics revolution is transforming how they treat cancer. They now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targetedtreatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers.They are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Their development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. | $60M / Private Equity / Mar 12, 2015 | |
Blueprint Medicines
|
Blueprint Medicines develops targeted therapies for cancer and blood disorders, focusing on precision medicine. The company utilizes genetic insights to design treatments tailored to individual patient needs. Their portfolio includes products aimed at specific mutations and conditions, enhancing treatment options for patients with various types ofcancer and hematologic diseases. Blueprint Medicines collaborates with healthcare providers to ensure that their therapies are accessible and effectively integrated into patient care. Through ongoing research and development, the company aims to expand its offerings and address unmet medical needs in oncology and hematology. | $50M / Series C / Nov 12, 2014 | |
Nexvet
|
Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs.Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines inhumans. We think it’s time companion animals reaped the benefits of human medical progress in this field.Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications.To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards.Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality. | $31.5M / Series B / Apr 16, 2014 | |
| See all 20 investments → | |||
Co-Investors
Tavistock Life Sciences
19 deals together
OrbiMed
4 deals together
EcoR1 Capital
3 deals together
LEAD
3 deals together
5AM Ventures
2 deals together
Baker Brothers Advisors LLC
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Tavistock Life Sciences invest in?
Tavistock Life Sciences invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tavistock Life Sciences?
Public channels for Tavistock Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tavistock Life Sciences?
The team at Tavistock Life Sciences includes Joe Lewis (Founder & Chairman) and Christopher Fuglesang (Team Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
